Michael F. Clarke, M.D.

Clinical Focus

• Cancer
• Colorectal Cancer
• Oncology
• Oncology (Cancer)

Honors and Awards

• Rackham Award, University of Michigan (-)
• American Society of Clinical Investigation, - (-)
• American Association of Physicians, - (-)

Professional Education

Postdoctoral Advisees

Maddalena Adorno , Shigeo Hisamori , Neethan Lobo , Ferenc Scheeren , Maider Zabala Ugalde

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Dr. Michael F. Clarke is the Associate Director of the Stanford Institute for Stem Cell and Regenerative Medicine. In addition to his clinical duties in the division of Oncology, Dr. Clarke maintains a laboratory focused on two areas of research: i) the control of self-renewal of normal stem cells and their malignant counterparts; and ii) the identification and characterization of cancer stem cells. A central issue in stem cell biology is to understand the mechanisms that regulate self-renewal of hematopoietic stem cells, which are required for hematopoiesis to persist for the lifetime of the animal. Until recently, the molecular mechanisms that regulate adult stem cell self-renewal were not known. His laboratory recently found that the proto-oncogene Bmi-1 regulates stem cell self-renewal via an epigenetic mechanism. By investigating the pathways upstream and downstream of Bmi1, the laboratory is actively investigating the molecular pathways that regulate self-renewal.

Cancers arise as a result of a series of genetic mutations. A better understanding of the consequences of these mutations on the underlying biology of the neoplastic cells will help to focus the development of more effective therapies. Solid tumors such as breast cancers contain heterogeneous populations of neoplastic cells. Dr. Clarke’s group has developed a technique that allows the isolation and characterization of tumorigenic and non-tumorigenic populations of cancer cells present in human breast, colon and head and neck cancer tumors. Only a small minority of cancer cells had the capacity to form new tumors in a xenograft model. This tumorigenic cell population could be identified prospectively and consistently had definable and identical phenotype. The tumorigenic cells displayed stem cell-like properties in that they were capable of generating new tumors containing additional stem cells as well as regenerating the phenotypically mixed populations of non-tumorigenic cells present in the...

Clinical Trials

• Biopsy of human tumors for cancer stem cell characterization: a feasibility study Recruiting

Publications

• Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF. Cell. 2009; 138 (3): 592-603
• Association of reactive oxygen species levels and radioresistance in cancer stem cells. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. Nature. 2009; 458 (7239): 780-3
• Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Akala OO, Park IK, Qian D, Pihalja M, Becker MW, Clarke MF. Nature. 2008; 453 (7192): 228-32
• The prognostic role of a gene signature from tumorigenic breast-cancer cells. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF. N Engl J Med. 2007; 356 (3): 217-26
• Stem cells and cancer: two faces of eve. Clarke MF, Fuller M. Cell. 2006; 124 (6): 1111-5